The phase 3 EXCALIBER-RRMM trial demonstrated PFS benefit for iberdomide, daratumamab, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma.
Related to this article
Telehealth transplant consults help patients with multiple myeloma overcome racial, age, and rural barriers, speeding eligibility screening and expanding access to specialists.
Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.
Degevma was approved for skeletal-related events in adults with bone metastases, giant cell tumor of bone, and the treatment of hypercalcemia of malignancy.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
SurVaxM Improves OS Only in Younger Subgroup in Newly Diagnosed Glioblastoma
2
Heng on Managing Toxicity and Sequencing With Belzutifan/Lenvatinib in RCC
3
How Allogeneic and In Vivo CAR T Could Expand Access
4
Phase 2 Data Show PFS Benefit With Carotuximab Combo in mCRPC
5